FERNANDO
PÉREZ RUIZ
Stanford University School of Medicine
Stanford, Estados UnidosPublicaciones en colaboración con investigadores/as de Stanford University School of Medicine (3)
2017
-
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study
Annals of the Rheumatic Diseases, Vol. 76, Núm. 10, pp. 1679-1687
2015
2014
-
Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout
Annals of the Rheumatic Diseases, Vol. 73, Núm. 1, pp. 177-182